CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Molecular Pharmacology (USA) Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Molecular Pharmacology (USA) Ltd
Drug Discovery Research Ctr
284 Oxford St
Phone: +61 894433011p:+61 894433011 LEEDERVILLE, WAS  6007  Australia Ticker: MLPHMLPH
This company ceased filing statements with the SEC on 3/5/2015.
Business Summary
Molecular Pharmacology (USA) Limited (Molecular USA) is an Australia-based development Stage company together with its subsidiary, Molecular Pharmacology Pty. Ltd. (MPLA) is in the business of developing and commercializing an analgesic and anti-inflammatory molecule known as Tripeptofen. The Company’s over-the-counter anti-pain and anti-inflammatory products sold for the treatment of acute localized pain are based on non-steroidal anti-inflammatory drugs (NSAIDs). The licensed products include all products in all dosage forms, formulations, line extensions and package configurations using production method of metallo-polypeptide analgesic and anti-inflammatory activity as an active ingredient marketed by MPLA or its affiliates under the trade name Tripeptofen. The Company and Molecular Pharmacology Pty. Ltd. have no manufacturing facilities.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/20146/30/2014YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President, Chief Executive Officer, Chief Financial Officer, Director Jeffery D.Edwards 1/1/2010 10/28/2005

Business Names
Business Name
BLUE HAWK VENTURES INC
MLPH
Molecular Pharmacology (USA) Ltd.
Molecular Pharmacology (USA) Ltd.

General Information
Outstanding Shares: 111,553,740 (As of 11/13/2014)
Shareholders: 19
Stock Exchange: OTC
Federal Tax Id: 710900799
Fax Number: +61 894433866


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, August 29, 2023